威高血净(603014.SH)发布公告，公司正在筹划以发行股份的方式购买山东威高普瑞医药包装有限公司 (以下简称"威高普瑞"或"标的公司")100%股权。经公司申请，公司股票自2025年10月20日(星期一)开市 起停牌，预计停牌时间不超过10个交易日。 ...

Core Viewpoint - Weigao Blood Purification (603014.SH) is planning to acquire 100% equity of Shandong Weigao Purui Pharmaceutical Packaging Co., Ltd. through a share issuance [1] Group 1 - The company has applied for a trading suspension, which will take effect from October 20, 2025, and is expected to last no more than 10 trading days [1]

Group 1 - The core point of the news is that Weigao Co., Ltd. has signed a non-binding letter of intent for a potential acquisition of 100% equity in Shandong Weigao Purui Pharmaceutical Packaging Co., Ltd. by issuing consideration shares to its shareholders [1] - The potential transaction involves Weigao Blood Purification, which is primarily engaged in the research, production, and sales of medical products for blood purification, including hemodialysis devices and peritoneal dialysis solutions [1] - As of the announcement date, Weigao Blood Purification is controlled by Weigao Group Co., Ltd., with Weigao Co., Ltd. holding a 23.53% stake in Weigao Blood Purification [1] Group 2 - Weigao Purui focuses on the research, production, and sales of pre-filled drug delivery systems and automatic safety drug delivery systems, aiming to provide comprehensive drug delivery solutions for global biopharmaceutical companies [2] - As of the announcement date, Weigao Purui is a non-wholly owned subsidiary of Weigao Co., Ltd., with ownership stakes of 94.0706%, 4.0215%, and 1.9078% held by Weigao Co., Ltd., Weihai Shengxi, and Weihai Ruiming, respectively [2] Group 3 - Related events include the potential injection of Weigao Blood Purification into Weigao Purui and the resignation of Yan Xia as Vice Chairman and Non-Executive Director of Weigao Co., Ltd. [3]

威高股份(01066)公布，于2025年10月17日，公司、威海盛熙企业管理咨询中心(有限合伙)(威海盛熙)、 威海瑞明企业管理咨询合伙企业(有限合伙)(威海瑞明)及山东威高血液净化制品股份有限公司(威高血净) 签订了一份不具法律约束力的意向书，据此威高血净向各威高普瑞股东发行对价股份以收购威高普瑞 100%的股权。 威高普瑞聚焦预灌封给药系统及自动安全给药系统等医药包材的研发、生产与销售，致力于为全球生物 制药企业提供一站式药品递送整体解决方案。截至本公告日期，威高普瑞为公司的非全资附属公司，由 公司、威海盛熙和威海瑞明分别持有94.0706%、4.0215%及1.9078%的股权。 董事会认为，潜在交易若可完成，威高普瑞与威高血净在业务上将产生协同效应，集团整体业务版图将 进一步扩大。 MACD金叉信号形成，这些股涨势不错！ 据悉，威高血净是一家在中国设立的公司，其A股在上海证券交易所上市(证券代码：603014.SH)。该公 司主要从事血液净化医用制品的研发、生产和销售，主要产品包括血液透析器、血液透析管路、血液透 析机以及腹膜透析液，分别围绕血液透析和腹膜透析领域，辅以透析配套产品的销售。截至本公告日 ...

Core Points - Weigao Blood Purification (603014.SH) is planning to acquire 100% equity of Shandong Weigao Purui Pharmaceutical Packaging Co., Ltd. through a share issuance, which will make Weigao Purui a wholly-owned subsidiary of the company [1] - The transaction is expected to constitute a major asset restructuring and related party transaction, but will not lead to a change in the actual controller of the company and does not constitute a restructuring listing [1] - The company has signed a Cooperation Intent Agreement with the transaction parties, outlining the preliminary intentions for the acquisition [1] Summary by Sections - **Transaction Details** - The acquisition is still in the planning stage, and the parties have not yet signed a formal transaction agreement [2] - The specific transaction plan is under negotiation and remains uncertain [2] - **Regulatory Approval** - The transaction requires approval from the company's board of directors, shareholders, and relevant regulatory authorities before it can be officially implemented [2] - There is uncertainty regarding whether the necessary approvals will be obtained and the timeline for such approvals [2] - **Stock Suspension** - To protect investor interests and ensure fair information disclosure, the company has applied for a trading suspension starting from October 20, 2025, for a period not exceeding 10 trading days [1]

Core Viewpoint - Weigao Group has signed a non-binding letter of intent for a potential acquisition of 100% equity in Shandong Weigao Purui Pharmaceutical Packaging Co., Ltd by Weigao Blood Purification Products Co., Ltd, indicating strategic expansion in the pharmaceutical packaging sector [1][2] Group 1: Company Overview - Weigao Blood Purification Products Co., Ltd is primarily engaged in the research, production, and sales of medical products for blood purification, including hemodialyzers, blood dialysis tubing, dialysis machines, and peritoneal dialysis solutions [1] - As of the announcement date, Weigao Blood Purification is controlled by Weigao Group, which holds a 23.53% direct stake in the company [1] Group 2: Weigao Purui Overview - Weigao Purui focuses on the research, production, and sales of pre-filled drug delivery systems and automatic safety drug delivery systems, aiming to provide comprehensive drug delivery solutions for global biopharmaceutical companies [2] - Weigao Purui is a non-wholly owned subsidiary of the company, with ownership stakes of 94.0706% by the company, 4.0215% by Weihai Shengxi, and 1.9078% by Weihai Ruiming [2]

Group 1 - Weigao Group has signed a non-binding letter of intent for a potential acquisition of 100% equity in Shandong Weigao Purui Pharmaceutical Packaging Co., Ltd by Weigao Blood Purification [1] - The potential transaction involves issuing consideration shares to Weigao Purui shareholders, which include Weigao Group and its affiliates [1] - Weigao Blood Purification is primarily engaged in the research, production, and sales of medical products for blood purification, including hemodialysis devices and peritoneal dialysis solutions [1] Group 2 - Weigao Purui focuses on the research, production, and sales of pre-filled drug delivery systems and automatic safety drug delivery systems, providing comprehensive drug delivery solutions for global biopharmaceutical companies [2] - As of the announcement date, Weigao Purui is a non-wholly owned subsidiary of the company, with ownership stakes of 94.0706%, 4.0215%, and 1.9078% held by the company, Weihai Shengxi, and Weihai Ruiming, respectively [2]

山東威高集團醫用高分子製品股份有限公 司 Shandong Weigao Group Medical Polymer Company Limited * （在中華人民共和國註冊成立的股份有限公司） （股份代號：1066） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告 全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 威高普瑞聚焦預灌封給藥系統及自動安全給藥系統等醫藥包材的研發、生產 與銷售，致力於為全球生物製藥企業提供一站式藥品遞送整體解決方案。截 至本公告日期，威高普瑞為本公司的非全資附屬公司，由本公司、威海盛熙和 威海瑞明分別持有94.0706%、4.0215%及1.9078%的股權。 董事會認為，潛在交易若可完成，威高普瑞與威高血淨在業務上將產生協同 效應，本集團整體業務版圖將進一步擴大。 上市規則涵義 自願公告 本公告乃由山東威高集團醫用高分子製品股份有限公司（「本公司」，連同其附 屬公司合稱「本集團」）自願刊發。 潛在交易 本公司董事會（「董事會」）謹此宣佈，於2025年10月17日（ ...

威高血净公告，公司正在筹划以发行股份的方式购买山东威高普瑞医药包装有限公司100%股权。本次 交易完成后，威高普瑞将成为公司的全资子公司。本次交易预计构成重大资产重组，构成关联交易，但 不会导致公司实际控制人的变更。目前，交易尚处于筹划阶段，存在不确定性。公司股票自2025年10月 20日起停牌，预计停牌时间不超过10个交易日。 ...

（记者 胡玲） 每经AI快讯，威高血净10月17日晚间发布公告称，因公司筹划发行股份购买资产暨关联交易事项山东 威高血液净化制品股份有限公司正在筹划以发行股份的方式购买山东威高普瑞医药包装有限公司100% 股权。本次交易完成后，威高普瑞将成为公司的全资子公司。经初步测算，本次交易预计构成重大资产 重组，构成关联交易。本次交易不会导致公司实际控制人的变更，不构成重组上市。为了维护投资者利 益，保证公平信息披露，避免对公司股价造成重大影响，经公司申请，公司股票自2025年10月20日（星 期一）开市起停牌，预计停牌时间不超过10个交易日。 每经头条（nbdtoutiao）——"我还在！"林园硬气回应牛市亏钱，"接下来，我还会在！"坚持白酒是"快 乐需求"，科技股买了"愁得睡不着" ...